vs
百利高（PRGO）与利氏兄弟拍卖行（RBA）财务数据对比。点击上方公司名可切换其他公司
利氏兄弟拍卖行的季度营收约是百利高的1.1倍（$1.2B vs $1.1B），利氏兄弟拍卖行净利率更高（9.1% vs -127.8%，领先136.9%），利氏兄弟拍卖行同比增速更快（5.4% vs -2.5%），利氏兄弟拍卖行自由现金流更多（$186.5M vs $148.6M），过去两年利氏兄弟拍卖行的营收复合增速更高（6.3% vs 1.3%）
百利高（Perrigo）是一家注册于爱尔兰的非处方仿制药生产商，主打自有品牌OTC药品业务。公司70%的净销售额来自美国医疗市场，为优化税务布局将法定总部设在爱尔兰，该地区销售额仅占总营收的0.6%，2013年曾完成美国历史上第六大企业税收倒置交易。
利氏兄弟拍卖行（股票代码RBA）是全球知名的工业资产拍卖服务商，注册地位于加拿大，属公开上市企业，总部设在美国伊利诺伊州韦斯特切斯特，普通股同时在多伦多证券交易所与纽约证券交易所挂牌交易。
PRGO vs RBA — 直观对比
营收规模更大
RBA
是对方的1.1倍
$1.1B
营收增速更快
RBA
高出7.9%
-2.5%
净利率更高
RBA
高出136.9%
-127.8%
自由现金流更多
RBA
多$37.9M
$148.6M
两年增速更快
RBA
近两年复合增速
1.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $1.2B |
| 净利润 | $-1.4B | $109.7M |
| 毛利率 | 32.6% | — |
| 营业利润率 | -116.0% | 14.7% |
| 净利率 | -127.8% | 9.1% |
| 营收同比 | -2.5% | 5.4% |
| 净利润同比 | -3093.9% | -7.4% |
| 每股收益（稀释后） | $-10.23 | $0.53 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PRGORBA
| Q4 25 | $1.1B | $1.2B | ||
| Q3 25 | $1.0B | $1.1B | ||
| Q2 25 | $1.1B | $1.2B | ||
| Q1 25 | $1.0B | $1.1B | ||
| Q4 24 | $1.1B | $1.1B | ||
| Q3 24 | $1.1B | $981.8M | ||
| Q2 24 | $1.1B | $1.1B | ||
| Q1 24 | $1.1B | $1.1B |
净利润PRGORBA
| Q4 25 | $-1.4B | $109.7M | ||
| Q3 25 | $7.5M | $95.5M | ||
| Q2 25 | $-8.4M | $109.8M | ||
| Q1 25 | $-6.4M | $113.4M | ||
| Q4 24 | $-44.4M | $118.5M | ||
| Q3 24 | $-21.0M | $76.1M | ||
| Q2 24 | $-108.4M | $111.1M | ||
| Q1 24 | $2.0M | $107.4M |
毛利率PRGORBA
| Q4 25 | 32.6% | — | ||
| Q3 25 | 36.1% | — | ||
| Q2 25 | 34.4% | — | ||
| Q1 25 | 37.6% | — | ||
| Q4 24 | 33.9% | — | ||
| Q3 24 | 37.2% | — | ||
| Q2 24 | 37.0% | — | ||
| Q1 24 | 33.1% | — |
营业利润率PRGORBA
| Q4 25 | -116.0% | 14.7% | ||
| Q3 25 | 7.0% | 14.5% | ||
| Q2 25 | 4.3% | 15.9% | ||
| Q1 25 | 4.5% | 17.1% | ||
| Q4 24 | 10.0% | 18.1% | ||
| Q3 24 | 7.4% | 15.6% | ||
| Q2 24 | -2.5% | 18.4% | ||
| Q1 24 | -5.1% | 18.7% |
净利率PRGORBA
| Q4 25 | -127.8% | 9.1% | ||
| Q3 25 | 0.7% | 8.7% | ||
| Q2 25 | -0.8% | 9.3% | ||
| Q1 25 | -0.6% | 10.2% | ||
| Q4 24 | -3.9% | 10.4% | ||
| Q3 24 | -1.9% | 7.8% | ||
| Q2 24 | -10.2% | 10.1% | ||
| Q1 24 | 0.2% | 10.1% |
每股收益（稀释后）PRGORBA
| Q4 25 | $-10.23 | $0.53 | ||
| Q3 25 | $0.05 | $0.43 | ||
| Q2 25 | $-0.06 | $0.53 | ||
| Q1 25 | $-0.05 | $0.55 | ||
| Q4 24 | $-0.32 | $0.58 | ||
| Q3 24 | $-0.15 | $0.36 | ||
| Q2 24 | $-0.79 | $0.54 | ||
| Q1 24 | $0.01 | $0.53 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $531.5M |
| 总债务越低越好 | — | $2.3B |
| 股东权益账面价值 | $2.9B | $5.6B |
| 总资产 | $8.5B | $12.1B |
| 负债/权益比越低杠杆越低 | — | 0.42× |
8季度趋势，按日历期对齐
现金及短期投资PRGORBA
| Q4 25 | — | $531.5M | ||
| Q3 25 | $432.1M | $674.7M | ||
| Q2 25 | $454.2M | $710.2M | ||
| Q1 25 | $409.9M | $578.1M | ||
| Q4 24 | $558.8M | $533.9M | ||
| Q3 24 | $1.5B | $650.7M | ||
| Q2 24 | $542.8M | $599.5M | ||
| Q1 24 | $658.5M | $462.8M |
总债务PRGORBA
| Q4 25 | — | $2.3B | ||
| Q3 25 | — | $2.6B | ||
| Q2 25 | — | $2.6B | ||
| Q1 25 | — | $2.6B | ||
| Q4 24 | — | $2.6B | ||
| Q3 24 | — | $2.7B | ||
| Q2 24 | — | $2.8B | ||
| Q1 24 | — | $2.9B |
股东权益PRGORBA
| Q4 25 | $2.9B | $5.6B | ||
| Q3 25 | $4.4B | $5.5B | ||
| Q2 25 | $4.5B | $5.5B | ||
| Q1 25 | $4.4B | $5.3B | ||
| Q4 24 | $4.3B | $5.2B | ||
| Q3 24 | $4.6B | $5.2B | ||
| Q2 24 | $4.5B | $5.2B | ||
| Q1 24 | $4.7B | $5.1B |
总资产PRGORBA
| Q4 25 | $8.5B | $12.1B | ||
| Q3 25 | $10.1B | $12.2B | ||
| Q2 25 | $10.1B | $12.2B | ||
| Q1 25 | $9.8B | $11.9B | ||
| Q4 24 | $9.6B | $11.8B | ||
| Q3 24 | $11.2B | $11.9B | ||
| Q2 24 | $10.4B | $12.1B | ||
| Q1 24 | $10.6B | $12.0B |
负债/权益比PRGORBA
| Q4 25 | — | 0.42× | ||
| Q3 25 | — | 0.47× | ||
| Q2 25 | — | 0.47× | ||
| Q1 25 | — | 0.50× | ||
| Q4 24 | — | 0.50× | ||
| Q3 24 | — | 0.52× | ||
| Q2 24 | — | 0.55× | ||
| Q1 24 | — | 0.58× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $175.4M | $255.2M |
| 自由现金流经营现金流 - 资本支出 | $148.6M | $186.5M |
| 自由现金流率自由现金流/营收 | 13.4% | 15.5% |
| 资本支出强度资本支出/营收 | 2.4% | 5.7% |
| 现金转化率经营现金流/净利润 | — | 2.33× |
| 过去12个月自由现金流最近4个季度 | $145.1M | $719.2M |
8季度趋势，按日历期对齐
经营现金流PRGORBA
| Q4 25 | $175.4M | $255.2M | ||
| Q3 25 | $51.7M | $239.7M | ||
| Q2 25 | $75.9M | $326.5M | ||
| Q1 25 | $-64.5M | $156.8M | ||
| Q4 24 | $312.6M | $184.5M | ||
| Q3 24 | $42.2M | $285.4M | ||
| Q2 24 | $9.5M | $337.3M | ||
| Q1 24 | $-1.4M | $124.8M |
自由现金流PRGORBA
| Q4 25 | $148.6M | $186.5M | ||
| Q3 25 | $29.8M | $188.5M | ||
| Q2 25 | $56.7M | $241.7M | ||
| Q1 25 | $-90.0M | $102.5M | ||
| Q4 24 | $274.9M | $127.9M | ||
| Q3 24 | $15.1M | $248.5M | ||
| Q2 24 | $-18.9M | $308.6M | ||
| Q1 24 | $-26.5M | $79.6M |
自由现金流率PRGORBA
| Q4 25 | 13.4% | 15.5% | ||
| Q3 25 | 2.9% | 17.3% | ||
| Q2 25 | 5.4% | 20.4% | ||
| Q1 25 | -8.6% | 9.2% | ||
| Q4 24 | 24.2% | 11.2% | ||
| Q3 24 | 1.4% | 25.3% | ||
| Q2 24 | -1.8% | 28.2% | ||
| Q1 24 | -2.4% | 7.5% |
资本支出强度PRGORBA
| Q4 25 | 2.4% | 5.7% | ||
| Q3 25 | 2.1% | 4.7% | ||
| Q2 25 | 1.8% | 7.2% | ||
| Q1 25 | 2.4% | 4.9% | ||
| Q4 24 | 3.3% | 5.0% | ||
| Q3 24 | 2.5% | 3.8% | ||
| Q2 24 | 2.7% | 2.6% | ||
| Q1 24 | 2.3% | 4.2% |
现金转化率PRGORBA
| Q4 25 | — | 2.33× | ||
| Q3 25 | 6.89× | 2.51× | ||
| Q2 25 | — | 2.97× | ||
| Q1 25 | — | 1.38× | ||
| Q4 24 | — | 1.56× | ||
| Q3 24 | — | 3.75× | ||
| Q2 24 | — | 3.04× | ||
| Q1 24 | -0.70× | 1.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
RBA
| Buyer Revenue | $577.2M | 48% |
| Seller Revenue | $255.2M | 21% |
| CA | $199.0M | 17% |
| Other | $124.7M | 10% |
| AU | $47.3M | 4% |
